Katarina Vucicevic , PhD, is a Full Professor of Pharmacokinetics and Clinical Pharmacy at the University of Belgrade – Faculty of Pharmacy and a U.S. Fulbright Scholar alumna. She completed a one-year postdoctoral fellowship in pharmacometrics at the Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco (UCSF). At the University of Belgrade, she teaches pharmacokinetics and clinical pharmacy at master's, doctoral, and specialization levels and supervises doctoral research in pharmacometrics. She also serves on national and international PhD defense committees. Her academic influence stems from an interdisciplinary approach to pharmacometrics and clinical pharmacokinetics, with a mission to bridge complex model-informed precision dosing and practical, real-world clinical decision-making. What distinguishes her in the field is her dedication to translating advanced pharmacometric methodologies into accessible tools for clinicians, particularly in the treatment of vulnerable populations requiring individualized pharmacotherapy. Her current research is focused on optimizing monoclonal antibody dosing regimen in patients with inflammatory bowel disease. Professor Vucicevic has authored or co-authored over 45 original scientific publications and has presented her work at numerous national and international conferences. She is the Principal Investigator of optYmAb (2024–2026), a national research project funded by the Science Fund of the Republic of Serbia and previously served as the Serbian lead in a bilateral research project with France (2023–2024). Her scholarly work has been cited over 700 times, with an h-index of 14 (Scopus). She co-authored the university textbook Pharmacokinetics and contributed to five book chapters in the field of clinical pharmacokinetics. Her contributions to academia extend beyond teaching and research. She has coordinated national and bilateral scientific projects, mentored numerous graduate and postgraduate students, and presided over the Scientific Committee of the 8th Congress of Pharmacists of Serbia. She serves as an external expert evaluator for bioequivalence studies and regulatory submissions for the Medicines and Medical Devices Agency of Serbia. In recognition of her achievements, she was awarded The Leader 2023 for five-year scientific excellence by the Fulbright and Friends Association. She is an active member of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Professor Vucicevic brings a unique combination of leadership, mentoring, communication, and problem-solving skills to her professional endeavors. Her experience in interdisciplinary and cross-cultural academic environments enhances her effectiveness as a collaborator and innovator in global health research. Outside academia, she is an avid 10K runner and enjoys traveling—pursuits that enrich her global outlook and inspire her commitment to international cooperation and scientific progress.